We are thrilled to announce that Brainify.AI has been recognized as an Honorable Mention in the Biotech category of the Nebius AI Discovery Awards 2025.
The Nebius AI Discovery Awards celebrate global startups using artificial intelligence to drive innovation in healthcare and life sciences. This year, over 100 companies from around the world competed for recognition across four categories: drug discovery, biotech, genomics & multiomics, and healthtech.
Our selection as an Honorable Mention underscores Brainify.AI’s impact in transforming raw EEG brainwave data into clinically actionable biomarkers, enabling precision drug development and personalized therapies for central nervous system (CNS) disorders.
As the only company translating Foundational Brain models into real-world diagnostic and therapeutic applications at scale, we are proud to contribute to a new era in neuroscience.
We congratulate all category winners and fellow honorees, and thank the Nebius team and judges for their support of the AI-driven healthcare ecosystem.
For more information about the awards, visit the Nebius AI Discovery Awards page.
“Being recognized by Nebius as an Honorable Mention is an important validation of our vision to bring precision medicine to neuroscience. Our team at Brainify.AI is committed to turning complex EEG brainwave data into powerful biomarkers that can accelerate drug development and improve patient outcomes worldwide.” - Mariam Khayretdinova, CEO, Brainify.AI